Press releaseGlobe Newswire
Eupraxia Pharmaceuticals
EPRX · TORONTO
$6.87−$0.72 (−9.49%)TodayMarket closed ·
Prev close $7.59
Latest news
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- NewsAvi Kapoor
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
- NewsAvi Kapoor
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsVandana Singh
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Proposed Public Offering
- NewsVandana Singh
Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
- NewsVandana Singh
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
- Press releaseGlobe Newswire
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
- Press releasePRNewswire
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.